JP2019534893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534893A5 JP2019534893A5 JP2019533297A JP2019533297A JP2019534893A5 JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5 JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019533297 A JP2019533297 A JP 2019533297A JP 2019534893 A5 JP2019534893 A5 JP 2019534893A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- ipr
- optionally substituted
- cancer
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384132P | 2016-09-06 | 2016-09-06 | |
| US62/384,132 | 2016-09-06 | ||
| US201762505064P | 2017-05-11 | 2017-05-11 | |
| US62/505,064 | 2017-05-11 | ||
| PCT/US2017/050106 WO2018048806A1 (en) | 2016-09-06 | 2017-09-05 | Cxcr4 antagonists and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534893A JP2019534893A (ja) | 2019-12-05 |
| JP2019534893A5 true JP2019534893A5 (https=) | 2020-08-20 |
| JP7100639B2 JP7100639B2 (ja) | 2022-07-13 |
Family
ID=61281979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533297A Expired - Fee Related JP7100639B2 (ja) | 2016-09-06 | 2017-09-05 | Ｃｘｃｒ４アンタゴニストおよび使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10351601B2 (https=) |
| EP (1) | EP3509612A4 (https=) |
| JP (1) | JP7100639B2 (https=) |
| CN (1) | CN109922818B (https=) |
| CA (1) | CA3032885C (https=) |
| WO (1) | WO2018048806A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| US10639379B2 (en) * | 2017-09-05 | 2020-05-05 | Mainline Biosciences Llc | High affinity CXCR4 selective binding conjugate and method for using the same |
| US11771736B2 (en) * | 2017-12-21 | 2023-10-03 | Mainline Biosciences (Shanghai) Co., Ltd. | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same |
| JP2023516878A (ja) * | 2020-01-26 | 2023-04-21 | メインライン バイオサイエンシーズ（シャンハイ）シーオー．，エルティーディ． | 同位体標識された選択的ｃｘｃｒ４結合性ペプチドコンジュゲート並びにその作製方法及び使用方法 |
| CA3243979A1 (en) * | 2022-02-11 | 2025-04-30 | C-Biomex Co., Ltd. | Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses |
| GB2628421A (en) * | 2023-03-24 | 2024-09-25 | Syntherix Ltd | Peptides and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1286684B1 (en) * | 2000-05-09 | 2004-04-28 | The University Of British Columbia | use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| JP5074661B2 (ja) * | 2002-12-26 | 2012-11-14 | 味の素株式会社 | 肝癌発生・進展抑制剤 |
| AP2081A (en) * | 2004-06-18 | 2010-01-04 | Ipf Pharmaceuticals Gmbh | Oligomeric peptides and their use for the treatment of HIV infections |
| US8628750B2 (en) * | 2006-02-27 | 2014-01-14 | Technische Universitat Munchen | Cancer imaging and treatment |
| EP2377579A1 (en) | 2007-05-30 | 2011-10-19 | Eli Lilly and Company | Cyclic peptide CXCR4 antagonists |
| IT1397901B1 (it) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| JP6294227B2 (ja) * | 2011-10-07 | 2018-03-14 | ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ | Ｆｐｒ１の阻害剤としてのテンプレート固定ペプチド模倣薬 |
| CN102626522B (zh) | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| JP6047231B2 (ja) | 2012-06-06 | 2016-12-21 | ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ | β−ヘアピンペプチド模倣薬 |
| US9790286B2 (en) * | 2013-01-02 | 2017-10-17 | Lucia Irene Gonzalez | Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis |
-
2017
- 2017-09-05 CN CN201780054250.5A patent/CN109922818B/zh not_active Expired - Fee Related
- 2017-09-05 US US15/695,862 patent/US10351601B2/en active Active
- 2017-09-05 WO PCT/US2017/050106 patent/WO2018048806A1/en not_active Ceased
- 2017-09-05 JP JP2019533297A patent/JP7100639B2/ja not_active Expired - Fee Related
- 2017-09-05 CA CA3032885A patent/CA3032885C/en active Active
- 2017-09-05 EP EP17849397.9A patent/EP3509612A4/en not_active Withdrawn
-
2019
- 2019-06-04 US US16/431,657 patent/US10870681B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534893A5 (https=) | ||
| JP7307744B2 (ja) | がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体 | |
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| EP2958571B1 (en) | Dna hypomethylating agents for cancer therapy | |
| JP2019514426A5 (https=) | ||
| JP2016505586A5 (https=) | ||
| JP2019503167A5 (https=) | ||
| JP2019527728A5 (https=) | ||
| JP2018532690A5 (https=) | ||
| JP2022514255A5 (https=) | ||
| JP2013518107A5 (https=) | ||
| JP2017525730A5 (https=) | ||
| JP2017509586A5 (https=) | ||
| JP2004534850A5 (https=) | ||
| JP2020532496A5 (https=) | ||
| WO2011148083A4 (fr) | Peptide en tant que médicament, en particulier pour le traitement du cancer | |
| JP2020097577A5 (https=) | ||
| JP2017006120A5 (https=) | ||
| JP2017523169A5 (https=) | ||
| JP2009511508A5 (https=) | ||
| JP2019519512A5 (https=) | ||
| JP2015520770A5 (https=) | ||
| JP2019507764A5 (https=) | ||
| JP2016531885A5 (https=) | ||
| JP2011518168A5 (https=) |